Cusatuzumab clinical trials
Also written ARGX-110 and JNJ-74494550.
- studies test it
- 7
- open now
- 0
- in phase 3
- 0
- first study started
- 2013
How each study uses cusatuzumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2019 (2)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2019 | 2 |
| 2020 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test cusatuzumab.
- Jan 2027A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive TherapyPhase 2 · OncoVerity, Inc.
- May 2027Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid LeukemiaPhase 1 · OncoVerity, Inc.
Studies
Open first, then newest update. How each study uses cusatuzumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive ChemotherapyActive, not recruitingPhase 2OncoVerity, Inc.NCT04023526Written as Cusatuzumab
- Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid LeukemiaActive, not recruitingPhase 1OncoVerity, Inc.NCT04150887Written as Cusatuzumab
- A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive TherapyActive, not recruitingPhase 2OncoVerity, Inc.NCT06384261Written as Cusatuzumab
- A Study of ARGX-110 in Participants With Advanced MalignanciesCompletedPhase 1/2OncoVerity, Inc.NCT01813539Written as ARGX-110
- A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS)CompletedPhase 1/2OncoVerity, Inc.NCT03030612Written as ARGX-110
- A Study of Cusatuzumab Plus Azacitidine in Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Who Are Not Candidates for Intensive TreatmentCompletedPhase 1OncoVerity, Inc.NCT04241549Written as Cusatuzumab
- A Study of ARGX-110 in Patients With Nasopharyngeal Carcinoma (NPC)CompletedPhase 1argenxNCT02759250Written as ARGX-110
Given beside what is tested · 1 — cusatuzumab is usual care or a partner of the new treatment
Codes
What other systems call cusatuzumab · ClinicalTrials.gg INT017819
- UNII (FDA) RR5U4UFJ8LCUSATUZUMABOne source FDA
- NCI Thesaurus C106116CusatuzumabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | RR5U4UFJ8L | CUSATUZUMAB | One source FDA |
| NCI Thesaurus | C106116 | Cusatuzumab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.